Novavax, Inc. (Nasdaq: NVAX), a US-based biotechnology company, announced on Monday that it has named John C Jacobs as its new president and chief executive officer and member of the board of directors effective 23 January 2023.
Jacobs is to replace Stanley C Erck, who will serve as an advisor to the company for the next fifteen months to enable a smooth transition.
Jacobs has over 25 years of commercial, operations, business and leadership experience across multiple therapeutic areas. He will join Novavax from Harmony Biosciences, where he has served as president and chief executive officer and a member of the board of directors since June 2018, and executive vice president and chief commercial officer from October 2017 to June 2018. He has served in leadership roles at Teva Pharmaceuticals, which includes senior vice president and general manager of the Respiratory Business Unit, senior vice president of Commercial Operations in North America, and general manager of Teva in Canada. He has also served in positions of increasing scope and responsibility at major pharmaceutical companies including Cephalon, Wyeth and Pfizer.
Bioforum, The Data Masters names new President
VolitionRx names new Chief Medical Officer
Quotient Sciences announces new appointments
Syndax Pharmaceuticals names new chief commercial officer
Everest Medicines names new chief medical officer and chief product officer
D3 Bio names new independent board member
Rigel Pharmaceuticals names new executive vice president and chief medical officer
Telix Pharmaceuticals names new group chief operating officer